keangkong
GLP-1 Specialist
- Member Since
- Sep 2, 2024
- Posts
- 1,819
- Likes Received
- 4,792
Arun, et al. (pre-publication, 2025). Survodutide- A Dual GLP-1 - Glucagon Agonist Reshaping Cardiometabolic Care. Cardiology Rev., https://doi.org/10.1097/crd.0000000000001062.
Awad, et al. (2025). Evaluating the efficacy and safety of survodutide for obesity - a systematic review and meta-analysis of randomized controlled trials. Baylor Univ. Med. Ctr. Proceedings 38(4), 514-522.
Bain & Williams (2024). Glucagon—a new player in weight management therapeutics[Q]. Lancet Diabetes & Endocrinology 12(3), P150-151,
Blüher, et al. (2024). Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon-GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes - a randomised clinical trial. Diabetologia 67, 470–482.
Dutta, et al. (2025). Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication -A Systematic Review and Meta-Analysis. Indian J. Endocrinology & Metabolism 29(3), 253-259.
Ekinci, et al. (2024). Subgroup analysis by gender and body mass index (BMI) in people living with overweight-obesity in the survodutide, a glucagon-GLP-1 receptor dual agonist, phase II trial. Obesity Res. & Clin. Pract. 18(5), S39.
Kaya, et al. (2024). Survodutide in MASH - bridging the gap between hepatic and systemic metabolic dysfunction. Expert Opn Investigational Drugs, 33(12), 1167–1176.
Klein, et al. (2024). Perspectives in weight control in diabetes – Survodutide. Diabetes Res. & Clin. Prac. 207, 110779.
Kosiborod, et al. (2024). Survodutide for the Treatment of Obesity - Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC - Heart Failure 12(12), 2101-2109.
Lawitz, et al. (2024). Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon-glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J. Hepatology, 81, 837-846.
Le Roux, et al. (2024). A Phase II, randomized, double-blind, placebo-controlled, dose-finding study of survodutide (BI 456906) in people living with overweight-obesity. Metabolism, 153, 155848.
Le Roux, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity - a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology 12(3), 162-173, 3, 162-173.
Le Roux, et al. (2024). 6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight-Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial. J. Endocrine Soc. 8 (Supplement_1).
Le Roux, et al. (2024). Survodutide, a glucagon receptor-GLP-1 receptor (GCGR-GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity - analysis of a placebo-controlled, randomised phase 2 trial. Eur. Heart J. 45(Supplement_1), ehae666-2895.
Long, et al. (2024). Hepatic GCGR is required for the superior weight loss effects of a structurally related analogue of the dual GCGR-LP1R agonist survodutide. Not yet certified by peer review, https://doi.org/10.1101/2024.09.09.611134.
Mikhail (2024). Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes. J. Endocrinology & Disorders 8(3), 01–04.
Nelson, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis - Results from a randomized, double-blind -controlled phase 2 trial. Obesity Res. & Clin. Pract. 18(5), S50.
Noureddin, et al. (2025). OS-098 Direct effects of survodutide on liver endpoints beyond weight loss - insights from a phase 2 trial of the glucagon receptor-glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis. J. Hepatology 82, S66–S67.
Noureddin, et al. (2025). SAT-445 Sustained improvements in non-invasive biomarkers with the novel glucagon receptor-glucagon-like peptide-1 receptor dual agonist survodutide - longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis. J. Hepatology 82, S636,
Sanyal, et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med. 391(4), 311-319. New England Journal of Medicine, 391(4), 311-319.
Sanyal, et al. (2024). O7 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis - results from a randomised, double-blind, placebo-controlled phase 2 trial. Gut 73, A4.
Schattenberg, et al. (2025). SAT-423 Survodutide, a glucagon/GLP-1 receptor dual agonist, in people with MASH with moderate-to-advanced liver fibrosis (stage F2-F3) - rationale and design of an event-driven, multinational, randomised, placebo-controlled, phase 3 trial (LIVERAGETM). J. Hepatology 82, S629-S630.
Targher, et al. (2025). Recent advances in incretin-based therapy for MASLD - from single to dual or triple incretin receptor agonists. Gut 74, 487-497.
Thomas, et al. (2024). The dual GCGR/GLP‐1R agonist survodutide - Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes Obesity & Metabolism 26(6), 2368–2378.
Vinton, et al. (2025). Survodutide: a novel peptide for treatment of obesity and metabolic diseases. Baylor Univ. Med. Ctr. Proceedings 38(4), 523.
Wan, et al. (2024). Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss - a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome, 16(1), 264.
Wharton, et al. (2024). Survodutide for treatment of obesity - rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE ‐1 and ‐2). Obesity, 33(1), 67–77. https://doi.org/10.1002/oby.24184
Xiao, et al. (pre-publication, 2025). Efficacy and safety of survodutide on glycemic control and weight loss in adults - A systematic review and meta‐analysis. Diabetes Obesity & Metabolism, https://doi.org/10.1111/dom.70105.
Zimmerman, et al. (2022). BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molec. Metabolism 66, 101633 ["When the potency was assessed in the presence of 100% human and mouse plasma, BI 456906 [survodutide] showed a potency of 1.0 and 1.6 nM for the human GLP-1R and 8.3 and 16 nM for the human GCGR, respectively].
Awad, et al. (2025). Evaluating the efficacy and safety of survodutide for obesity - a systematic review and meta-analysis of randomized controlled trials. Baylor Univ. Med. Ctr. Proceedings 38(4), 514-522.
Bain & Williams (2024). Glucagon—a new player in weight management therapeutics[Q]. Lancet Diabetes & Endocrinology 12(3), P150-151,
Blüher, et al. (2024). Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon-GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes - a randomised clinical trial. Diabetologia 67, 470–482.
Dutta, et al. (2025). Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication -A Systematic Review and Meta-Analysis. Indian J. Endocrinology & Metabolism 29(3), 253-259.
Ekinci, et al. (2024). Subgroup analysis by gender and body mass index (BMI) in people living with overweight-obesity in the survodutide, a glucagon-GLP-1 receptor dual agonist, phase II trial. Obesity Res. & Clin. Pract. 18(5), S39.
Kaya, et al. (2024). Survodutide in MASH - bridging the gap between hepatic and systemic metabolic dysfunction. Expert Opn Investigational Drugs, 33(12), 1167–1176.
Klein, et al. (2024). Perspectives in weight control in diabetes – Survodutide. Diabetes Res. & Clin. Prac. 207, 110779.
Kosiborod, et al. (2024). Survodutide for the Treatment of Obesity - Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC - Heart Failure 12(12), 2101-2109.
Lawitz, et al. (2024). Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon-glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J. Hepatology, 81, 837-846.
Le Roux, et al. (2024). A Phase II, randomized, double-blind, placebo-controlled, dose-finding study of survodutide (BI 456906) in people living with overweight-obesity. Metabolism, 153, 155848.
Le Roux, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity - a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology 12(3), 162-173, 3, 162-173.
Le Roux, et al. (2024). 6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight-Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial. J. Endocrine Soc. 8 (Supplement_1).
Le Roux, et al. (2024). Survodutide, a glucagon receptor-GLP-1 receptor (GCGR-GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity - analysis of a placebo-controlled, randomised phase 2 trial. Eur. Heart J. 45(Supplement_1), ehae666-2895.
Long, et al. (2024). Hepatic GCGR is required for the superior weight loss effects of a structurally related analogue of the dual GCGR-LP1R agonist survodutide. Not yet certified by peer review, https://doi.org/10.1101/2024.09.09.611134.
Mikhail (2024). Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes. J. Endocrinology & Disorders 8(3), 01–04.
Nelson, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis - Results from a randomized, double-blind -controlled phase 2 trial. Obesity Res. & Clin. Pract. 18(5), S50.
Noureddin, et al. (2025). OS-098 Direct effects of survodutide on liver endpoints beyond weight loss - insights from a phase 2 trial of the glucagon receptor-glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis. J. Hepatology 82, S66–S67.
Noureddin, et al. (2025). SAT-445 Sustained improvements in non-invasive biomarkers with the novel glucagon receptor-glucagon-like peptide-1 receptor dual agonist survodutide - longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis. J. Hepatology 82, S636,
Sanyal, et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med. 391(4), 311-319. New England Journal of Medicine, 391(4), 311-319.
Sanyal, et al. (2024). O7 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis - results from a randomised, double-blind, placebo-controlled phase 2 trial. Gut 73, A4.
Schattenberg, et al. (2025). SAT-423 Survodutide, a glucagon/GLP-1 receptor dual agonist, in people with MASH with moderate-to-advanced liver fibrosis (stage F2-F3) - rationale and design of an event-driven, multinational, randomised, placebo-controlled, phase 3 trial (LIVERAGETM). J. Hepatology 82, S629-S630.
Targher, et al. (2025). Recent advances in incretin-based therapy for MASLD - from single to dual or triple incretin receptor agonists. Gut 74, 487-497.
Thomas, et al. (2024). The dual GCGR/GLP‐1R agonist survodutide - Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes Obesity & Metabolism 26(6), 2368–2378.
Vinton, et al. (2025). Survodutide: a novel peptide for treatment of obesity and metabolic diseases. Baylor Univ. Med. Ctr. Proceedings 38(4), 523.
Wan, et al. (2024). Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss - a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome, 16(1), 264.
Wharton, et al. (2024). Survodutide for treatment of obesity - rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE ‐1 and ‐2). Obesity, 33(1), 67–77. https://doi.org/10.1002/oby.24184
Xiao, et al. (pre-publication, 2025). Efficacy and safety of survodutide on glycemic control and weight loss in adults - A systematic review and meta‐analysis. Diabetes Obesity & Metabolism, https://doi.org/10.1111/dom.70105.
Zimmerman, et al. (2022). BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molec. Metabolism 66, 101633 ["When the potency was assessed in the presence of 100% human and mouse plasma, BI 456906 [survodutide] showed a potency of 1.0 and 1.6 nM for the human GLP-1R and 8.3 and 16 nM for the human GCGR, respectively].
